Roohi Gajee

Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results

Courtney D. DiNardo, Joseph Rosenthal, Michael Andreeff et al. · Blood · 2016 · 37 citations

Medicine, Hematology, Oncology +11

A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.

Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz et al. · Journal of Clinical Oncology · 2016 · 23 citations

Medicine, Oncology, Pharmacology +17

Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects

Alexander G. Vandell, Satoshi Inoue, Justin Dennie et al. · Antimicrobial Agents and Chemotherapy · 2018 · 18 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

Analysis of doxorubicin in cell culture media and human plasma using solid phase extraction and HPLC

Paul W. Buehler, Steven J. Robles, Guy R. Adami et al. · Chromatographia · 1999 · 16 citations

Pharmacy, Biochemistry, Pharmacology +8

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

Hamim Zahir, Fumiaki Kobayashi, Cynthia Zamora et al. · The Journal of Clinical Pharmacology · 2020 · 13 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15